HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics

BACKGROUND: Therapies targeting anti-tumor T-cell responses have proven successful in the treatment of a variety of malignancies. However, as most patients still fail to respond, approaches to augment immunotherapeutic efficacy are needed. Here, we investigated the ability of histone deacetylase 6 (...

Descripción completa

Detalles Bibliográficos
Autores principales: Laino, Andressa S., Betts, B. C., Veerapathran, A., Dolgalev, I., Sarnaik, A., Quayle, S. N., Jones, S. S., Weber, J. S., Woods, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366050/
https://www.ncbi.nlm.nih.gov/pubmed/30728070
http://dx.doi.org/10.1186/s40425-019-0517-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366050/
https://www.ncbi.nlm.nih.gov/pubmed/30728070
http://dx.doi.org/10.1186/s40425-019-0517-0

Ejemplares similares